Modulation of insulin secretion in noninsulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166

Diabetic Medicine

Volumn 13, Issue SUPPL. 6, 1996, Pages

  Kikuchi, M ^a  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

Author keywords

A4166; NN623; Non sulphonylureas

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; INSULIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; REPAGLINIDE;

BIOAVAILABILITY; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL;

EID: 0029817751     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/dme.1996.13.s6.151     Document Type: Conference Paper

References (15)

1. Owens DR, Donockley W, Robling MR, et al. Dose-response study of a new (non-suphonylurea) agent in diet treated patients with non-insulin dependent diabetes mellitus (NIDDM). Report for Vth World Conference on Clinical Pharmacology and Therapeutics, Yokohama, 1992; Abstract No 0-36-01.
2. Greischell A, Beshke K, Rapp H, et al. Quantitation of the new hypoglycaemic agent AG-EE 388 ZW in human plasma by automated high-performance liquid chromatography with electrochemical detection. J Chromatography 1991; 568: 246-252.
3. Shinkai H, Toi K, Kumashiro I, et al. NA-Acylphenylalanines and related compounds. A new class of oral hypoglycaemic agents. J Med Chem 1988; 31: 2092-2097
4. Shinkai H, Nishikawa N, Sata Y, et al. N-(cyclohexylcarbonyl)-D-phenylalaines and related compounds. A new class of oral hypoglycaemic agents. J Med Chem 1989; 32: 1436-1441.
5. Sato Y, Nishikawa M, Shinkai H. High performance liquid chromatographic method for quantitation of a new antidiabetic agent in plasma. J Liquid Chromatogr 1988; 11: 3425-3433.
6. Tsukuda K, Sakurada M, Kikuchi M. Insulin secretion in vitro by a D-phenylalanine derivative. Diabetologia 1991; 34(suppl 2): A91.
7. Frokjaer-Jensen J, Kofod H, Godtfredsen SE. Mechanism of action of AG-EE 623 ZW, a novel insulinotropic agent. Diabetologia 1992; 35(suppl 1): A116.
8. Akiyoshi M, Kakei M, Nakazaki M, et al. A new hypoglycaemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am J Physiol 1995; 268 (Endocrinol Metab 31): E185-E193.
9. 2+ influx. Endocrinology 1994; 134: 1395-1400.
10. Ampudia-Blasco FJ, Heinemann L, Bender R, et al. Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects. Diabetologia 1994; 37: 703-707.
11. Wahlin-boll E, Melander A, Sartor G, et al. Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects Eur J Clin Pharmacol 1980; 18: 279-283.
12. Groop L, Luzi L, Melander A, et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987; 36: 1320-1328.
13. Kikuchi M, Kuzuya T, Akanuma Y, et al. Early phase II study of a novel oral hypoglycaemic agent, A4166, in Japan. Abstracts of 15th IDF Committee, Kobe. 1994: 418.
14. DeFronzo R, Simonson DC. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin dependent diabetic individuals. Diabetes Care 1984; 7(suppl 1): 72-80.
15. Imatake M, Ogihara N, Ebihara S, et al. Suppression by D-phenylaline derivative, A4166, of postprandial hyperglycaemia in dogs. Diabetologia 1994; 37(suppl 1): A210.